Double-blind randomized placebo-controlled clinical trial of omega 3 fatty acids for the treatment of diabetic patients with nonalcoholic steatohepatitis

Journal of Clinical Gastroenterology

Volumn 49, Issue 2, 2015, Pages 137-144

  Dasarathy, Srinivasan ^a   Dasarathy, Jaividhya ^b   Khiyami, Amer ^b   Yerian, Lisa ^a   Hawkins, Carol ^b   Sargent, Ruth ^a   Mccullough, Arthur J ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b METROHEALTH MEDICAL CENTER   (United States)

Author keywords

diabetes mellitus; nonalcoholic steatohepatitis; polyunsaturated fatty acids

Indexed keywords

DOCOSAHEXAENOIC ACID; GLUCOSE; HEMOGLOBIN A1C; ICOSAPENTAENOIC ACID; OMEGA 3 FATTY ACID; PLACEBO; BIOLOGICAL MARKER; MICROCAPSULE;

ADULT; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DUAL ENERGY X RAY ABSORPTIOMETRY; FATTY LIVER; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; LABORATORY TEST; LIVER BIOPSY; LIVER HISTOLOGY; MALE; NONALCOHOLIC FATTY LIVER; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; BIOPSY; BLOOD; CLINICAL TRIAL; DRUG COMBINATION; INTENTION TO TREAT ANALYSIS; MICROCAPSULE; MIDDLE AGED; MULTICENTER STUDY; NON-ALCOHOLIC FATTY LIVER DISEASE; ORAL DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; ADULT; BIOMARKERS; BIOPSY; CAPSULES; DIABETES MELLITUS; DOCOSAHEXAENOIC ACIDS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EICOSAPENTAENOIC ACID; FEASIBILITY STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; INTENTION TO TREAT ANALYSIS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OHIO; PILOT PROJECTS; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84921603820     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000099     Document Type: Article

References (60)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
2. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307:491-497.
3. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943-951.
4. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524-530.
5. Pagadala MR, McCullough AJ. The relevance of liver histology to predicting clinically meaningful outcomes in nonalcoholic steatohepatitis. Clin Liver Dis. 2012;16:487-504.
6. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steato-hepatitis in the United States. Gastroenterology. 2011;141: 1249-1253.
7. Neuschwander-Tetri BA, Clark JM, Bass NM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52:913-924.
8. Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262-265.
9. Zein CO, Unalp A, Colvin R, et al. Smoking and severity of hepatic fibrosis in nonalcoholic fatty liver disease. J Hepatol. 2011;54:753-759.
10. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836-1846.
11. Musso G, Gambino R, Cassader M, et al. A meta-Analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology. 2010;52:79-104.
12. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010;362:1675-1685.
13. Promrat K, Kleiner DE, Niemeier HM, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51:121-129.
14. Kromhout D, Yasuda S, Geleijnse JM, et al. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work?. Eur Heart J. 2012;33:436-443.
15. Parker HM, Johnson NA, Burdon CA, et al. Omega-3 supplementation and non-Alcoholic fatty liver disease: a systematic review and meta-Analysis. J Hepatol. 2012;56:944-951.
16. Ducheix S, Montagner A, Polizzi A, et al. Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. J Hepatol. 2013;58: 984-992.
17. Kim HJ, Lee KT, Park YB, et al. Dietary docosahexaenoic acid-rich diacylglycerols ameliorate hepatic steatosis and alter hepatic gene expressions in C57BL/6 J-Lep(ob/ob) mice. Mol Nutr Food Res. 2008;52:965-973.
18. Pawar A, Jump DB. Unsaturated fatty acid regulation of peroxisome proliferator-Activated receptor alpha activity in rat primary hepatocytes. J Biol Chem. 2003;278:35931-35939.
19. Zuniga J, Cancino M, Medina F, et al. N-3 PUFA supplementation triggers PPAR-Alpha activation and PPAR-Alpha/NF-kappaB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury. PLoS One. 2011;6:e28502.
20. Lombardo YB, Chicco AG. Effects of dietary polyunsaturated n-3 fatty acids on dyslipidemia and insulin resistance in rodents and humans. A review. J Nutr Biochem. 2006;17:1-13.
21. Xu J, Nakamura MT, Cho HP, et al. Sterol regulatory element binding protein-1 expression is suppressed by dietary poly-unsaturated fatty acids. A mechanism for the coordinate suppression of lipogenic genes by polyunsaturated fats. J Biol Chem. 1999;274:23577-23583.
22. Al-Gayyar MM, Shams ME, Barakat EA. Fish oil improves lipid metabolism and ameliorates inflammation in patients with metabolic syndrome: impact of nonalcoholic fatty liver disease. Pharm Biol. 2012;50:297-303.
23. Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr Opin Lipidol. 2008;19:242-247.
24. Li H, Ruan XZ, Powis SH, et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-gamma-dependent mechanism. Kidney Int. 2005;67: 867-874.
25. Ishii H, Horie Y, Ohshima S, et al. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hep-Atocyte-specific Pten-deficient mice. J Hepatol. 2009;50:562-571.
26. Grimsgaard S, Bonaa KH, Hansen JB, et al. Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids. Am J Clin Nutr. 1997;66:649-659.
27. Rambjor GS, Walen AI, Windsor SL, et al. Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans. Lipids. 1996;31(suppl):S45-S49.
28. Saynor R, Gillott T. Changes in blood lipids and fibrinogen with a note on safety in a long term study on the effects of n-3 fatty acids in subjects receiving fish oil supplements and followed for seven years. Lipids. 1992;27:533-538.
29. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement: executive summary. Crit Pathw Cardiol. 2005;4:198-203.
30. Kleiner DE, Brunt EM, Van NM, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321.
31. McKenney JM, Sica D. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia. Pharmacother-Apy. 2007;27:715-728.
32. Capanni M, Calella F, Biagini MR, et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-Alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther. 2006;23:1143-1151.
33. Chen R, Guo Q, Zhu W, et al. Therapeutic efficacy of (omega)-3 polyunsaturated fatty acid capsule in the treatment of patients with non-Alcoholic fatty liver disease. World Chin J Digestol. 2008;16:2002-2006.
34. Cussons AJ, Watts GF, Mori TA, et al. Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy. J Clin Endocrinol Metab. 2009;94:3842-3848.
35. Hatzitolios A, Savopoulos C, Lazaraki G, et al. Efficacy of omega-3 fatty acids, atorvastatin and orlistat in non-Alcoholic fatty liver disease with dyslipidemia. Indian J Gastroenterol. 2004;23:131-134.
36. Nobili V, Bedogni G, Alisi A, et al. Docosahexaenoic acid supplementation decreases liver fat content in children with non-Alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Arch Dis Child. 2011;96:350-353.
37. Sofi F, Giangrandi I, Cesari F, et al. Effects of a 1-year dietary intervention with n-3 polyunsaturated fatty acid-enriched olive oil on non-Alcoholic fatty liver disease patients: a preliminary study. Int J Food Sci Nutr. 2010;61:792-802.
38. Spadaro L, Magliocco O, Spampinato D, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis. 2008;40:194-199.
39. Tanaka N, Sano K, Horiuchi A, et al. Highly purified eicosapentaenoic acid treatment improves nonalcoholic stea-Tohepatitis. J Clin Gastroenterol. 2008;42:413-418.
40. Vega GL, Chandalia M, Szczepaniak LS, et al. Effects of N-3 fatty acids on hepatic triglyceride content in humans. J Investig Med. 2008;56:780-785.
41. Zhu FS, Liu S, Chen XM, et al. Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia. World J Gastroenterol. 2008;14:6395-6400.
42. Musso G, Gambino R, De MF, et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology. 2003;37:909-916.
43. Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol. 2012;56:1145-1151.
44. Cortez-Pinto H, Jesus L, Barros H, et al. How different is the dietary pattern in non-Alcoholic steatohepatitis patients?. Clin Nutr. 2006;25:816-823.
45. Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061-1067.
46. Froyland L, Vaagenes H, Asiedu DK, et al. Chronic administration of eicosapentaenoic acid and docosahexaenoic acid as ethyl esters reduced plasma cholesterol and changed the fatty acid composition in rat blood and organs. Lipids. 1996;31:169-178.
47. Willumsen N, Hexeberg S, Skorve J, et al. Docosahexaenoic acid shows no triglyceride-lowering effects but increases the peroxisomal fatty acid oxidation in liver of rats. J Lipid Res. 1993;34:13-22.
48. Li Y, Chen D. The optimal dose of omega-3 supplementation for non-Alcoholic fatty liver disease. J Hepatol. 2012;57: 468-469.
49. Saravanan P, Davidson NC, Schmidt EB, et al. Cardiovascular effects of marine omega-3 fatty acids. Lancet. 2010;376: 540-550.
50. Hartweg J, Perera R, Montori V, et al. Omega-3 polyunsatu-rated fatty acids (PUFA) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2008;CD003205.
51. Chitturi S. Treatment options for nonalcoholic fatty liver disease. Therap Adv Gastroenterol. 2008;1:173-189.
52. Hoofnagle JH, Van Natta ML, Kleiner DE, et al. Vitamin E and changes in serum alanine aminotransferase levels in patients with non-Alcoholic steatohepatitis. Aliment Pharmacol Ther. 2013;38:134-143.
53. Larter CZ, Yeh MM, Cheng J, et al. Activation of peroxisome proliferator-Activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol. 2008;23:267-275.
54. Sugiyama E, Ishikawa Y, Li Y, et al. Eicosapentaenoic acid lowers plasma and liver cholesterol levels in the presence of peroxisome proliferators-Activated receptor alpha. Life Sci. 2008;83:19-28.
55. Kotwal S, Jun M, Sullivan D, et al. Omega 3 fatty acids and cardiovascular outcomes: systematic review and meta-Analysis. Circ Cardiovasc Qual Outcomes. 2012;5:808-818.
56. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-Analysis. JAMA. 2012;308:1024-1033.
57. Roncaglioni MC, Tombesi M, Avanzini F, et al. n-3 fatty acids in patients with multiple cardiovascular risk factors. N Engl J Med. 2013;368:1800-1808.
58. Brasky TM, Darke AK, Song X, et al. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst. 2013;105:1132-1141.
59. Fernandez ML, West KL. Mechanisms by which dietary fatty acids modulate plasma lipids. J Nutr. 2005;135:2075-2078.
60. Masterton GS, Plevris JN, Hayes PC. Review article: omega-3 fatty acids - a promising novel therapy for non-Alcoholic fatty liver disease. Aliment Pharmacol Ther. 2010;31:679-692.